Cx601: Phase III started

TiGenix began the double-blind, placebo-controlled, European Phase III ADMIRE-CD trial to evaluate Cx601 in about

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE